Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Acute Leukemia: early-phase trial registry
21 of 38 indexed Acute Leukemia trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #393 of 28,707 conditions by registered trial count.
38 US clinical trials · 21 currently recruiting · #393 of 28,707 conditions by registered trial count
Acute Leukemia: 38 US clinical trials tracked, 21 recruiting.
Acute Leukemia is the subject of 38 registered US clinical trials on ClinicalTrials.gov, 21 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 22 in Phase 1-2 (earlier-stage). The most active sponsor is City of Hope Medical Center, running 5 of these trials.
Enrollment posture brief
Registry condition acute-leukemia
OPEN 21 | RECR 55% | LATE 1 | EARLY 22 | RANK #393 | SPON 5
Volume-matched condition peers
Nearest open-share peer: Diffuse Intrinsic Pontine Glioma (55% recruiting · 29 trials)
Acute Leukemia lists 21 open slots (55% of 38 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Acute Leukemia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Acute Leukemia is recruiting above its size-band peers.
21 of 38 indexed trials (55.3%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Acute Leukemia trials is spread across many organizations.
City of Hope Medical Center accounts for 5 of 38 trials (13.2%). 25 distinct sponsors appear on at least one study for this condition label.
-
Most Acute Leukemia trials plan to enrol fewer than 100 people.
Median target enrolment is 68 among the 38 trials that report a genuine target (sentinel values excluded). 23 of those (60.5%) plan for fewer than 100 participants.
-
Acute Leukemia research is mostly interventional.
31 interventional and 7 observational studies make up this index (81.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
38 total, page 1 of 1
Familial Investigations of Childhood Cancer Predisposition
St. Jude Children's Research Hospital
NCT03050268
Identify Barriers to Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed and Relapsed Acute Leukemia
Memorial Sloan Kettering Cancer Center
NCT02677064
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Masonic Cancer Center, University of Minnesota
NCT03314974
Standard-of-Care Reduced-Intensity Conditioning (RIC) With 200 Versus 400 cGy of Total Body Irradiation (TBI) in Patients With Acute Leukemia Undergoing First Allogeneic Blood or Marrow Transplantation (BMT)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT06803745
Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)
Fred Hutchinson Cancer Center
NCT03970096
Tools for Reducing Inequity in Acute Leukemia (TRIAL): Beta Testing
Dana-Farber Cancer Institute
NCT06907797
MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
Masonic Cancer Center, University of Minnesota
NCT05735717
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
Fred Hutchinson Cancer Center
NCT03779854
Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft
Stanford University
NCT05088356
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
Fred Hutchinson Cancer Center
NCT04195633
Trial of 2 Step ATG for Prevention of Acute GVHD Post Allogeneic Stem Cell Transplant
University of Alabama at Birmingham
NCT06265584
A Study of Revumenib and Mezigdomide in People With Leukemia
Memorial Sloan Kettering Cancer Center
NCT07356154
CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT
Children's Hospital of Philadelphia
NCT03810196
Umbilical Cord Blood Transplantation From Unrelated Donors
University of Rochester
NCT03016806
Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant
University of Alabama at Birmingham
NCT06315309
Revumenib for the Treatment of Acute Leukemia in Patients Post-Allogeneic Stem Cell Transplant
City of Hope Medical Center
NCT06575296
BMT-06: Study of Intensity Modulated Total Marrow Irradiation (IM-TMI)
University of Illinois at Chicago
NCT04187105
Brain MRF in Children, Adolescents and Young Adults With Acute Leukemia
Case Comprehensive Cancer Center
NCT06421155
AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion
Mitchell Cairo
NCT04099966
A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)
University of Chicago
NCT06207123
A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
Ossium Health
NCT05589896
Cytogenetic Studies in Acute Leukemia and Multiple Myeloma
Alliance for Clinical Trials in Oncology
NCT00048958
Collecting and Storing Blood, Bone Marrow, and Other Samples From Patients With Acute Leukemia, Chronic Leukemia, or Myelodysplastic Syndromes
Alliance for Clinical Trials in Oncology
NCT00899223
A High Intensity Electronic Health Intervention for the Reduction of Learning Disparities in Childhood Cancer Survivors
City of Hope Medical Center
NCT05428176
HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis
Center for International Blood and Marrow Transplant Research
NCT06001385
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
Center for International Blood and Marrow Transplant Research
NCT04904588
Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
Orca Biosystems
NCT04013685
High-Intensity Parent Intervention Program in Improving Learning and School Functioning in Latino Children With Acute Leukemia or Lymphoblastic Lymphoma
City of Hope Medical Center
NCT03178617
Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
Orca Biosystems
NCT05316701
Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelofibrosis Undergoing Reduced Intensity Conditioning Donor Stem Cell Transplantation
City of Hope Medical Center
NCT04339101
Prevention of Hospital Acquired Deconditioning in Hospitalized Acute Leukemia Patients
Northwell Health
NCT07122479
Cancer Stem Cells in Acute Leukemia
Sanford Health
NCT03735797
TBI Using IMRT (VMAT or Tomotherapy) for the Prevention of Pul Toxicities in Patients Undergoing Donor SCT
City of Hope Medical Center
NCT04281199
Pilot of a Trial Enrollment Diversity Dashboard
Dana-Farber Cancer Institute
NCT06795139
Evaluation of the BD OneFlow Acute Leukemia Panel on the BD FACSLyric Flow Cytometer
Becton, Dickinson and Company
NCT05035615
Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)
National Heart, Lung, and Blood Institute (NHLBI)
NCT02208037
Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System
National Cancer Institute (NCI)
NCT00520130
CD34 Selected Allogeneic HCT w/ Myeloablative Conditioning Plus CD8+ Memory TCell Infusion in MDS, AL and CML
Robert Lowsky
NCT04151706
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 8 |
| Phase 2 | 14 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Acute Leukemia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Acute Leukemia trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Acute Leukemia page
38 registered trials, 21 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 21 Acute Leukemia trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- City of Hope Medical Center sponsors the most Acute Leukemia trials on record, review their full trial history before evaluating a specific study. See City of Hope Medical Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Acute Leukemia condition card totals 38 registered trials; most-linked intervention Fludarabine; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.